MPR Weekly Dose Podcast #260 — Top 2026 Health Trends With US News’ Annika Urban
Release Date: 01/16/2026
MPR Weekly Dose Podcast #283 — mRNA Influenza Vaccine; Pluvicto for PSMA+ mHSPC; Mucinex 12HR Approved; Narcolepsy Tx Approved; Peanut Allergy Treatment Fast Tracked
MPR Weekly Dose
Moderna’s mRNA influenza vaccine gains FDA approval; approvals for prostate cancer, narcolepsy type 1 and Mucinex 12HR; and peanut allergy treatment gains Fast Track status.
info_outline
MPR Weekly Dose Podcast #282 — OTC Acetaminophen/Naproxen; Novel ADHD Tx; COVID-19 PEP; Contraceptive Patch; Furosemide Autoinjector for Edema
MPR Weekly Dose
An over-the-counter acetaminophen/naproxen sodium fixed-dose tablet gains approval; Simtriyo approved for ADHD; Xocova approved for COVID-19 postexposure prophylaxis; A new contraceptive patch is approved; and Furoscix ReadyFlow approval is expanded to treat edema in CHF, CKD.
info_outline
MPR Weekly Dose Podcast #281 — Kalshi Start Clinical Trial Predictions; Positive Results for Retatrutide; Jideytro Approved; Smart Toilet Launches; Daraxonrasib NDA Accepted
MPR Weekly Dose
Kalshi start clinical trials, FDA approvals prediction market; positive results shared for triple hormone therapy retatrutide; Jideytro gains approval in advanced or metastatic ROS1-positive NSCLC; a smart toilet seat hits the market to measure your vitals; and the FDA accepts an application for pretreated metastatic pancreatic cancer treatment, daraxonrasib.
info_outline
MPR Weekly Dose Podcast #280 — Cyclospora Outbreak Latest; Hypercholesterolemia Tx Approved; New Lecanemab SC Regimen; Oral Sleep Apnea Tx; Revtorpyk Approved for Breast Cancer
MPR Weekly Dose
The latest on the multistate cyclospora outbreak; Lipfendra approved to reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia; subcutaneous starting dose regimen approved for Leqembi; NDA accepted for oral sleep apnea treatment; and Revtorpyk combination approved for advanced breast cancer.
info_outline
MPR Weekly Dose Podcast #279 — Trutakna Approved; Xtoro and Amerithroid Now Available; Casgevy Approval Expanded; Lupus Tx Granted Breakthrough Designation
MPR Weekly Dose
A new treatment is approved to reduce proteinuria in adults with primary immunoglobulin A nephropahty; a swimmer’s ear treatment and the thyroid hormone replacement therapy Amerithroid are now available; Casgevy approval expanded include pediatrics; and a lupus treatment is granted breakthrough status.
info_outline
MPR Weekly Dose Podcast #278 — Once-Weekly HIV Tx; Hympavzi Approval Expanded; Orforglipron Assessed in Menopause; Warning Label for Weight Loss Tx
MPR Weekly Dose
A single, once-weekly tablet could change HIV treatment landscape; weight loss drug orforglipron efficacy assessed at all stages of menopause; hemophilia treatment Hympavzi gains expanded indication; and the FDA adds a warning label for kidney injury to an over-the-counter weight loss aid.
info_outline
MPR Weekly Dose Podcast #277 — Treatment Approved for cUTI; COVID-19 Postexposure Prophylaxis; Eye Drops Fail to Meet Endpoint; Afrezza Indication Expanded; Obefazimod UC Trial Results
MPR Weekly Dose
New treatment approved for adults with complicated urinary tract infections; Xocova approved for COVID-19 postexposure prophylaxis; investigational diabetic macular edema eye drop fails to meet trial endpoint; Afrezza expanded for pediatric use; obefazimod looks promising for ulcerative colitis.
info_outline
MPR Daily Dose Podcast #276 — Retatrutide Shows Significant Weight Loss; Hepcludex Approved; Acne Gel for OTC Use; Linzess Indication Expanded; Camizestrant Review Extended
MPR Weekly Dose
New triple hormone receptor agonist shows significant weight loss; hepatitis delta virus treatment gains accelerated approval; acne gel gains OTC designation; constipation treatment expanded to include younger patients; and the FDA extends review for camizestrant in advanced breast cancer.
info_outline
MPR Daily Dose #275 — Top OTC Meds and Products; FDA Assess Safety in Pregnancy; Efgartigimod gMG Indication Broadened; R/R Mantle Cell Lymphoma Approval; ALS Treatment Fast Tracked
MPR Weekly Dose
US News and World Report releases their annual best over-the-counter products list; new guidance for drug safety evaluation during pregnancy; gMG indication broadened for efgartigimod; Beqalzi gains accelerated approval for MCL; and a novel treatment fast tracked for ALS.
info_outline
MPR Weekly Dose Podcast #274 — Ozempic Tablets; ALS Tx Fast Tracked; Phase 3 results for aficamten in HCM; Motion Sickness Drug Approved; Lantus Alternative
MPR Weekly Dose
Ozempic tablets are now available; investigational ALS treatment gains FDA Fast Track status; positive results for aficamten in non-obstructive hypertrophic cardiomyopathy; motion sickness drug Nereus now available; Lantus alternative Langlara gains approval.
info_outlineFifty-eight health experts have weighed in on the future of wellness. In this episode, we sit down with Annika Urban, health editor for US News and World Report, to analyze the implications of these findings. Annika shares her perspective on the major shifts happening across the health spectrum.